1 to 9 of 10 results

Bladder cancer market to witness moderate growth by 2017, despite anticipated launch of EOoquin

Bladder cancer market to witness moderate growth by 2017, despite anticipated launch of EOoquin


The bladder cancer therapeutics market in the six major countries is forecast to climb from $239.3 million…

EOquinEuropeMarkets & MarketingOncologyPharmaceuticalSpectrum PharmaceuticalsUSA

Ligand to earn up to $50 million in deal with Spectrum for Captisol-enabled melphalan


Ligand Pharmaceuticals (Nasdaq: LGND) has signed a global license and supply agreements with fellow US…

FinancialLicensingLigand PharmaceuticalsmelphalanOncologyPharmaceuticalSpectrum Pharmaceuticals

Global epigenetic therapies market to increase at a CAGR of 10% through 2017


The global epigenetic therapies market is expected to reach a total value of around $2.518 billion by…

belinostatBiotechnologyCelgeneFaridakGlobalMarkets & MarketingNovartisOncologypanobinostatPharmaceuticalSpectrum PharmaceuticalsTopotargetVidaza

Topotarget says belinostat pivotal trial meets primary endpoint


Denmark's Topotarget (Nasdaq OMX: TOPO) said that the primary endpoint has been met for the pivotal trial…

belinostatOncologyPharmaceuticalResearchSpectrum PharmaceuticalsTopotarget

Spectrum plunges on negative trial results; makes bid for Allos


US biotech firm Spectrum Pharmaceuticals (Nasdaq: SPPI) saw its shares plunge as much as 14%, before…

Allos TherapeuticsapaziquoneBiotechnologyFolotynMergers & AcquisitionsOncologyPharmaceuticalResearchSpectrum Pharmaceuticals

Spectrum in-licenses novel GCSF drug from Hanmi Pharma


USA-based Spectrum Pharmaceuticals (NasdaqGS: SPPI) has entered into a co-development and commercialization…

Hanmi PharmaceuticalLicensingOncologyPharmaceuticalSpectrum Pharmaceuticals

Spectrum Pharma to acquire non-US rights to market Zevalin


USA-based Spectrum Pharmaceuticals (NasdaqGS: SPPI) says it has entered into an agreement to acquire…

BayerMergers & AcquisitionsOncologyPharmaceuticalSpectrum PharmaceuticalsZevalin

US FDA approves J&J’s Zytiga for late-stage prostate cancer and Spectrum’s Fusilev for metastatic colorectal cancer


Ahead of the holiday weekend, the US Food and Drug Administration announced a couple of new drug approvals:…

BiotechnologyFusilevJohnson & JohnsonNorth AmericaOncologyPharmaceuticalRegulationSpectrum PharmaceuticalsZytiga

1 to 9 of 10 results



Back to top